CRBP Latest Headlines

Corbus Pharmaceuticals Announces Retirement of Board Member Holmer

at www.tipranks.com (Thu, 18-Dec 4:36 PM)

Corbus Prepares to Release Phase 1a Results for CRB-913—A Next-Gen Obesity Drug with Significantly Lower Brain Penetration

Market Chameleon (Thu, 11-Dec 10:34 AM)

CRBP’s Phase 1a Results Reveal Favorable Safety Profile and Notable Early Weight Loss with CRB-913

Market Chameleon (Thu, 11-Dec 7:06 AM)

CRBP Announces $75 Million Public Offering: Focus on Advancing Oncology and Obesity Pipeline

Market Chameleon (Fri, 31-Oct 8:20 AM)